Wave 80 Biosciences specializes in the development and enhancement of homogeneous assays, which are designed to detect probes and targets entirely in the solution phase. This innovative approach mitigates common issues associated with solid-phase assays, such as binding epitope availability and confounding effects, thereby broadening the applications of these assays across various clinical needs. The company’s technology focuses on improving assay performance through advanced signaling methods, probe design, and sample preparation techniques, particularly in challenging environments where low-concentration target analytes are present.

One of Wave 80's key innovations is the Infra technology, which addresses sample preparation challenges in molecular testing and sequencing, ensuring the recovery of low-concentration analytes from complex biological matrices like sputum. Additionally, the company employs Liquid Micropiston (LMP) technology, which enhances assay kinetics and scalability while maintaining low manufacturing costs. Wave 80's collaborative projects, such as those aimed at improving infectious disease diagnostics for military medics and developing tools for studying HIV pathogenesis, highlight their commitment to advancing patient outcomes through innovative assay solutions.

United States

Wave 80 Biosciences is a healthcare technology company that develops next-generation molecular diagnostics instruments and consumables for various human health conditions with a unique one patient-one test model.

Wave 80 Biosciences

Company Details